Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Joel Isaacson & Co. LLC

Joel Isaacson & Co. LLC reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,132 shares of the medical instruments supplier’s stock after selling 55 shares during the quarter. Joel Isaacson & Co. LLC’s holdings in Becton, Dickinson and Company were worth $996,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Nordea Investment Management AB increased its position in shares of Becton, Dickinson and Company by 277.3% in the 1st quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock valued at $478,295,000 after acquiring an additional 1,423,353 shares during the period. PineStone Asset Management Inc. raised its stake in shares of Becton, Dickinson and Company by 141.6% in the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after purchasing an additional 788,735 shares during the last quarter. M&G Plc acquired a new stake in shares of Becton, Dickinson and Company during the first quarter worth about $173,692,000. First Eagle Investment Management LLC boosted its position in Becton, Dickinson and Company by 32.5% in the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock valued at $655,149,000 after buying an additional 688,296 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Becton, Dickinson and Company by 8.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after buying an additional 346,720 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.2 %

Shares of BDX stock opened at $238.13 on Friday. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $259.92. The company has a market cap of $68.82 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 1.79 and a beta of 0.42. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The stock has a 50 day simple moving average of $237.43 and a 200-day simple moving average of $235.18.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same period last year, the company posted $2.96 EPS. Becton, Dickinson and Company’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, equities research analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Analyst Ratings Changes

BDX has been the topic of several recent research reports. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Raymond James decreased their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.